UK MPs wants pharma in AIDS patent pool, while GSK makes new moves
This article was originally published in Scrip
Executive Summary
The prices of newer second-line antiretroviral treatments (ARTs) need to be urgently reduced to improve access to developing countries, says a new report by a group of UK members of Parliament. The report, The Treatment Timebomb, states that by 2030 more than 50 million people will need ARTs worldwide, compared with just nine million today.